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BACKGROUND In the setting of primary percutaneous coronary
intervention (PPCI), patients with a concurrent chronic total occlusion
(CTO) in a non-infarct related artery (IRA) were recently identiﬁed as a
high-risk subgroup. It is unclear whether ST-elevation myocardial
infarction (STEMI) patients with a CTO in a non-IRA should undergo
additional percutaneous coronary intervention of the chronic total
occlusion on top of optimal medical therapy shortly after PPCI.
Possible beneﬁcial effects include reduction in adverse left ventricular
remodeling and preservation of global left ventricular function and
improved long term clinical outcome.
METHODS The EXPLORE trial is a global randomized, prospective,
multicenter, two-arm trial with blinded evaluation of endpoints. A
total of 304 patients were included after successful PPCI for STEMI
with a concurrent CTO in a non-IRA and were randomized to either
elective PCI of the CTO within 7 days or standard medical treatment.
Primary endpoints are left ventricular ejection fraction and left ven-
tricular end-diastolic volume assessed by cardiac Magnetic Resonance
Imaging at four months, analyzed by an independent corelab. All
events underwent independent monitoring and were adjudicated by
an independent critical events committee. Furthermore, all angiog-
raphies were reviewed by an independent corelab.
RESULTS In total, 304 STEMI patients with a CTO were included from
07-11-2007 until 30-03-2015. Data is currently analyzed.
CONCLUSIONS The ongoing EXPLORE trial is the ﬁrst randomized
clinical trial powered to investigate whether recanalization of a chronic
total occlusion in a non-infarct related artery after primary percuta-
neous coronary intervention for ST-elevation myocardial infarction
results in a better preserved residual left ventricular ejection fraction,
reduced end-diastolic volume and enhanced clinical outcome.
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BACKGROUND A major determinant of mortality and morbidity is the
extent of myocardial necrosis after STEMI, and strategies to limit
infarct size may therefore improve prognosis. As recently demon-
strated in human studies, pressure-controlled intermittent coronary
sinus occlusion (PICSO) may enhance myocardial recovery in acute
myocardial infarction. Whether coronary sinus occlusion should be
established before reperfusion is unknown.
METHODS In a prospective, controlled study, 28 pigs undergoing 90 mi-
nutes of left anterior descending (LAD) coronary artery balloon occlusion
followed by reperfusion were randomly assigned to 3 groups: Early PICSO(starting 10 minutes prior to reperfusion, group A, n¼9), Late PICSO
(starting 30 minutes post reperfusion, group B, n¼10), or reperfusion only
(group C, n¼9). PICSO was administered in an automatic mode for 90 mi-
nutes after initiation. Mean PICSO quantity was deﬁned as the sum of the
coronary sinus pressuremodulation for all PICSO cycles. Infarct size (% left
ventricular mass), microvascular obstruction (MVO), and left ventricular
function were assessed by cardiac magnetic resonance imaging (MRI) on
day 5. VEGF receptor expression was assessed by immunohistochemistry
after sacriﬁce on day 5.
RESULTS The histologic andMRI groupmean values for percent infarct
sizewere numerically lowest in GroupAwhen compared to GroupB and
Group C, albeit not reaching signiﬁcance (13.5%5.8% vs. 16.6%3.6%
vs. 16.2%4.2% respectively, p¼0.31). The same was true for MVO
(3.2%3.5% vs. 6.4%7.7% vs. 8.8%7.1% respectively, p¼0.16).
However, left ventricular ejection fraction (LVEF) was greatest in the
Early PICSO group (61.07.0% vs. 50.29.8% vs. 52.37.3% respec-
tively, p¼0.02), as was wall thickening (49.715.0 vs. 33.715.1 vs.
39.57.0 respectively, p¼0.045). Compared to control, group A animals
had 3-fold greater expression ofVEGF-R1 in themyocardial zone remote
from the infarct (median [IQR] 19 [12-24] vs. 9 [6.8-11.5] vs. 5 [3.5-8]
respectively, p¼0.001). Group B animals had 2-fold greater expression
of VEGF-R2 in the border zone of the infarct compared to control (5 [3.5-
9], 14.5 [9.5-16], 6 [5-12.5], respectively). No safety issues were noted.
CONCLUSIONS PICSO was safely applied in a porcine model of LAD
infarction. MRI at day 5 showed greater LVEF, better wall thickening,
and trends toward smaller infarct size and MVO in animals treated
with early PICSO, suggesting a cardioprotective effect of PICSO. In
addition, PICSO resulted in an increased VEGF-R1 expression in the
remote zone and VEGF-R2 in the border zone indicating, increased
neo-angiogenic activity. Large trials are underway to demonstrate the
beneﬁts of PICSO in humans.
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BACKGROUND When performing percutaneous coronary interven-
tion (PCI) for long-diffuse lesions, the best revascularization strategy
remains unclear with options including treating most of the vessel
length as opposed to a focal approach. A common option is to create a
“full-metal jacket (FMJ)”. However, FMJ may preclude future surgical
revascularization and may be associated with higher events rates at
follow-up. The use of bioresorbable scaffolds (BRS) is therefore very
attractive by virtue of their full reabsorption 2 to 3 years after
implantation. We aimed to investigate the feasibility and updated
clinical outcomes following BRS implantation for very long lesions
(“full-plastic jacket”).
METHODS We analyzed consecutive patients who underwent PCI with
Absorb BRS (Abbott Vascular, Santa Clara, CA) between May 2012 and
April 2015. Procedural “full-plastic jacket” (FPJ) was deﬁned as a
continuous implantation of BRS with 60mm length or more. During the
study period, 290 lesions (196 patients) treated with BRS (total length<
60mm) and 35 lesions (35 patients) treated with FPJ were identiﬁed.
RESULTS Patients treated with FPJ had a higher prevalence of dia-
betes (40.0% vs. 22.4%, p¼0.03), chronic total occlusion (17.1% vs.
